-
公开(公告)号：US20190038763A1
公开(公告)日：2019-02-07
申请号：US16073141
申请日：2017-01-27
申请人： INSERM (INSTITUTE NATIONAL DE LA SANTÉ ET DE LA RECHERCHE MÉDICALE) , UNIVERSITÉ PAUL SABATIER TOULOUSE III , CENTRE HOSPITALIER UNIVERSITAIRE DE TOULOUSE
发明人： Thierry LEVADE , Bruno SEGUI , Nicolas MEYER , Céline COLACIOS VIATGÉ , Nathalie ANDRIEU-ABADIE , Florie BERTRAND
摘要： The present invention relates to methods and pharmaceutical composition for the treatment of cancer. In particular, the present invention relates to a method for enhancing the potency of an immune checkpoint inhibitor administered to a subject as part of a treatment regimen for cancer, the method comprising: administering a pharmaceutically effective amount of a TNFα blocking agent to a subject in combination with the immune checkpoint inhibitor.
-
公开(公告)号：US20210145977A1
公开(公告)日：2021-05-20
申请号：US17146798
申请日：2021-01-12
申请人： INSERM (INSTITUT NATIONAL DE LA SANTÉ ET DE LA RECHERCHE MÉDICALE) , UNIVERSITÉ PAUL SABATIER TOULOUSE III , CENTRE HOSPITALIER UNIVERSITAIRE DE TOULOUSE
发明人： Thierry LEVADE , Bruno SEGUI , Nicolas MEYER , Céline COLACIOS VIATGÉ , Nathalie ANDRIEU-ABADIE , Florie BERTRAND
IPC分类号： A61K47/68 , C07K16/24 , C07K16/28 , A61K39/395 , A61P35/00
摘要： The present invention relates to methods and pharmaceutical composition for the treatment of cancer. In particular, the present invention relates to a method for enhancing the potency of an immune checkpoint inhibitor administered to a subject as part of a treatment regimen for cancer, the method comprising: administering a pharmaceutically effective amount of a TNFα blocking agent to a subject in combination with the immune checkpoint inhibitor.
-
公开(公告)号：US20170174744A1
公开(公告)日：2017-06-22
申请号：US15310158
申请日：2015-05-12
申请人： INSERM(INSTITUT NATIONAL DE LA SANTÉ ET DE LA RECHERCHE MÉDICALE , CENTRE HOSPITALIER UNIVERSITAIRE DE TOULOUSE , INSTITUT CLAUDIUS REGAUD , UNIVERSITÉ PAULS SABATIER TOULOUSE III
发明人： Bruno SEGUI , Nathalie ANDRIEU-ABADIE , Thierry LEVADE , Celine COLACIOS VIATGE , Philippe ROCHAIX , Florie BERTRAND , Herve BENOIST , Julia ROCHOTTE
IPC分类号： C07K14/715 , G01N33/574 , C07K16/30 , A61K38/17 , C07K16/24
CPC分类号： C07K14/7151 , A61K38/1793 , A61K2039/505 , A61K2039/55 , C07K16/241 , C07K16/2878 , C07K16/3053 , C07K2317/21 , C07K2317/24 , C07K2317/76 , C07K2319/30 , G01N33/5743 , G01N2333/525 , G01N2333/70539
摘要： The present invention relates to a TNFα blocking agent for use in the treatment and prevention of melanoma in a subject in whom melanoma cells express MHCI and in whom stroma cells exhibit TNF expression.
-
4.发明申请公开(公告)号：US20190031756A1
公开(公告)日：2019-01-31
申请号：US16074555
申请日：2017-02-01
申请人： INSERM (INSTITUTE NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE) , UNIVERSITE PAUL SABATIER TOULOUSE III , CENTRE HOSPITALIER UNIVERSITAIRE DE TOULOUSE
发明人： Thierry LEVADE , Bruno SEGUI , Florie BERTRAND , Julia ROCHOTTE , Anne MONTFORT , Nathalie ANDRIEU-ABADIE , Celine COLACIOS VIATGE , Nicolas MEYER
IPC分类号： C07K16/28 , C12N9/16 , G01N33/569 , A61P35/00 , A61K9/127
摘要： The present invention relates to methods and pharmaceutical compositions for enhancing CD8+ T cell-dependent immune responses in subjects suffering from cancer. In particular, the present invention relates to a method of enhancing the CD8+ T cell-dependent immune response in a subject suffering from cancer comprising administering to the subject a therapeutically effective amount of an agent capable of increasing intra-tumoral ceramide content.
-
-
-
搜索结果
4 条记录 (耗时 0.039 秒)
